Negative effects of progesterone receptor isoform-A on human placental activity of the noncanonical NF-κB signaling

Journal of Clinical Endocrinology and Metabolism

Volumn 99, Issue 2, 2014, Pages

  Wang, Bingbing ^a   Parobchak, Nataliya ^a   Rosen, Max ^a   Roche, Natalie ^b   Rosen, Todd ^a  

^a ROBERT WOOD JOHNSON MEDICAL SCHOOL   (United States)

^b RUTGERS NEW JERSEY MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CORTICOTROPIN-RELEASING HORMONE; CYCLOOXYGENASE 2; DOWN-REGULATION; FEMALE; HUMANS; HYDROXYPROGESTERONES; NF-KAPPA B; PLACENTA; PREGNANCY; PROGESTERONE; PROTEIN ISOFORMS; RECEPTORS, PROGESTERONE; SIGNAL TRANSDUCTION; UP-REGULATION;

EID: 84893797403     PISSN: 0021972X     EISSN: 19457197     Source Type: Journal    
DOI: 10.1210/jc.2013-2721     Document Type: Article

References (39)

1. Goldenberg RL, Culhane JF, Iams JD, Romero R. Epidemiology and causes of preterm birth. Lancet. 2008;371:75-84.
2. Mathews TJ, Menacker F, MacDorman MF; Centers for Disease C and Prevention; National Center for Health Statistics. Infant mortality statistics from the 2002 period: linked birth/infant death data set. Natl Vital Stat Rep. 2004;53:1-29.
3. Meis PJ, Klebanoff M, Thom E, et al; National Institute of Child Health and Human Development Maternal-Fetal Medicine Units Network. Prevention of recurrent preterm delivery by 17-hydroxyprogesterone caproate. N Engl J Med. 2003;348:2379-2385.
4. Norwitz ER, Caughey AB. Progesterone supplementation and the prevention of preterm birth. Rev Obstet Gynecol. 2011;4:60-72.
5. Fonseca EB, Celik E, Parra M, Singh M, Nicolaides KH; Fetal Medicine Foundation Second Trimester Screening Group. Progesterone and the risk of preterm birth among women with a short cervix. N Engl J Med. 2007;357:462-469.
6. Hassan SS, Romero R, Vidyadhari D, et al; PREGNANT Trial. Vaginal progesterone reduces the rate of preterm birth in women with a sonographic short cervix: a multicenter, randomized, doubleblind, placebo-controlled trial. Ultrasound Obstet Gynecol. 2011; 38:18-31.
7. Brown AG, Leite RS, Strauss JF 3rd. Mechanisms underlying "functional" progesterone withdrawal at parturition. Ann N Y Acad Sci. 2004;1034:36-49.
8. Tibbetts TA, Conneely OM, O'Malley BW. Progesterone via its receptor antagonizes the pro-inflammatory activity of estrogen in the mouse uterus. Biol Reprod. 1999;60:1158-1165.
9. Jacobsen BM, Horwitz KB. Progesterone receptors, their isoforms and progesterone regulated transcription. Mol Cell Endocrinol. 2012;357:18-29.
10. Wei LL, Norris BM, Baker CJ. An N-Terminally truncated third progesterone receptor protein, PR(C), forms heterodimers with PR(B) but interferes in PR(B)-DNA binding. J Steroid Biochem Mol Biol. 1997;62:287-297.
11. Saner KJ, Welter BH, Zhang F, et al. Cloning and expression of a novel, truncated, progesterone receptor.MolCell Endocrinol. 2003; 200:155-163.
12. Taylor AH, McParland PC, Taylor DJ, Bell SC. The cytoplasmic 60 kDa progesterone receptor isoform predominates in the human amniochorion and placenta at term. Reprod Biol Endocrinol. 2009;7: 22.
13. Karalis K, Goodwin G, Majzoub JA. Cortisol blockade of progesterone: a possible molecular mechanism involved in the initiation of human labor. Nat Med. 1996;2:556-560.
14. McLean M, Bisits A, Davies J, Woods R, Lowry P, Smith R. A placental clock controlling the length of human pregnancy. Nat Med. 1995;1:460-463.
15. Petraglia F, Imperatore A, Challis JR. Neuroendocrine mechanisms in pregnancy and parturition. Endocr Rev. 2010;31:783-816.
16. Wang B, Palomares K, Parobchak N, et al. Glucocorticoid receptor signaling contributes to constitutive activation of the noncanonical NF-B pathway in term human placenta. Mol Endocrinol. 2013; 27:203-211.
17. Wang B, Parobchak N, Rosen T. RelB/NF-B2 Regulates Corticotropin- ReleasingHormonein theHumanPlacenta.MolEndocrinol. 2012;26:1356-1369.
18. Wadhwa PD, Garite TJ, Porto M, et al. Placental corticotropinreleasing hormone (CRH), spontaneous preterm birth, and fetal growth restriction: a prospective investigation. Am J Obstet Gynecol. 2004;191:1063-1069.
19. Meis PJ, Aleman A. Progesterone treatment to prevent preterm birth. Drugs. 2004;64:2463-2474.
20. Padayachi T, Pegoraro RJ, Rom L, Joubert SM. Enzyme immunoassay of oestrogen and progesterone receptors in uterine and intrauterine tissue during human pregnancy and labour. J Steroid Biochem Mol Biol. 1990;37:509-511.
21. Shanker YG, Rao AJ. Progesterone receptor expression in the human placenta. Mol Hum Reprod. 1999;5:481-486.
22. Tang Z, Tadesse S, Norwitz E, Mor G, Abrahams VM, Guller S. Isolation of hofbauer cells from human term placentas with high yield and purity. Am J Reprod Immunol. 2011;66:336-348.
23. Ni X, Hou Y, Yang R, Tang X, Smith R, Nicholson RC. Progesterone receptors A and B differentially modulate corticotropin-releasing hormone gene expression through a cAMP regulatory element. Cell Mol Life Sci. 2004;61:1114-1122.
24. Chivers JE, Cambridge LM, Catley MC, et al. Differential effects of RU486 reveal distinct mechanisms for glucocorticoid repression of prostaglandin E release. Eur J Biochem. 2004;271:4042-4052.
25. Wagner BL, Pollio G, Giangrande P, et al. The novel progesterone receptor antagonists RTI 3021-012 and RTI 3021-022 exhibit plex glucocorticoid receptor antagonist activities: implications for the development of dissociated antiprogestins. Endocrinology. 1999;140:1449-1458.
26. Bain DL, Heneghan AF, Connaghan-Jones KD, MiuraMT.Nuclear receptor structure: implications for function. Annu Rev Physiol. 2007;69:201-220.
27. Guiochon-Mantel A, Lescop P, Christin-Maitre S, Loosfelt H, Perrot- Applanat M, Milgrom E. Nucleocytoplasmic shuttling of the progesterone receptor. EMBO J. 1991;10:3851-3859.
28. Coope HJ, Atkinson PG, Huhse B, et al. CD40 regulates the processing of NF-B2 p100 to p52. EMBO J. 2002;21:5375-5385.
29. Derudder E, Dejardin E, Pritchard LL, Green DR, Korner M, Baud V. RelB/p50 dimers are differentially regulated by tumor necrosis factor- and lymphotoxin- receptor activation: critical roles for p100. J Biol Chem. 2003;278:23278-23284.
30. Sun SC. Non-canonical NF-B signaling pathway. Cell Res. 2011; 21:71-85.
31. Dejardin E, Droin NM, Delhase M, et al. The lymphotoxin- receptor induces different patterns of gene expression via two NF-B pathways. Immunity. 2002;17:525-535.
32. Smith R. Parturition. N Engl J Med. 2007;356:271-283.
33. Smith R, Smith JI, Shen X, et al. Patterns of plasma corticotropinreleasing hormone, progesterone, estradiol, and estriol change and the onset of human labor. J Clin Endocrinol Metab. 2009;94:2066-2074.
34. Marx SG, Wentz MJ, Mackay LB, et al. Effects of progesterone on iNOS, COX-2, and collagen expression in the cervix. J Histochem Cytochem. 2006;54:623-639.
35. Riley SC, Walton JC, Herlick JM, Challis JR. The localization and distribution of corticotropin-releasing hormone in the human placenta and fetal membranes throughout gestation. J Clin Endocrinol Metab. 1991;72:1001-1007.
36. Xu Y, Knipp GT, Cook TJ. Expression of cyclooxygenase isoforms in developing rat placenta, human term placenta, and BeWo human trophoblast model. Mol Pharm. 2005;2:481-490.
37. Robinson BG, Emanuel RL, Frim DM, Majzoub JA. Glucocorticoid stimulates expression of corticotropin-releasing hormone gene in human placenta. Proc Natl Acad Sci U S A. 1988;85:5244-5248.
38. Mendelson CR. Fetal-maternal hormonal signaling in pregnancy and labor. Mol Endocrinol. 2009;23:947-954.
39. Gill RM, Ni J, Hunt JS. Differential expression of LIGHT and its receptors in human placental villi and amniochorion membranes. Am J Pathol. 2002;161:2011-2017.